Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (3), 113-35

History of the Discovery and Clinical Introduction of Chlorpromazine


History of the Discovery and Clinical Introduction of Chlorpromazine

Francisco López-Muñoz et al. Ann Clin Psychiatry.


Background: The historical process of discovery and clinical introduction of chlorpromazine, one of the greatest advances of 20th century medicine and history of psychiatry, is analyzed.

Methods: In this review, we have studied the original works of pioneers in the discovery and clinical use of chlorpromazine, as well as the contributions of prestigious researchers (historians, pharmacologists, psychiatrists, etc.) about this topic.

Results: The discovery of phenothiazines, the first family of antipsychotic agents has its origin in the development of German dye industry, at the end of the 19th century (Graebe, Liebermann, Bernthsen). Up to 1940 they were employed as antiseptics, antihelminthics and antimalarials (Ehrlich, Schulemann, Gilman). Finally, in the context of research on antihistaminic substances in France after World War II (Bovet, Halpern, Ducrot) the chlorpromazine was synthesized at Rhône-Poulenc Laboratories (Charpentier, Courvoisier, Koetschet) in December 1950. Its introduction in anaesthesiology, in the antishock area (lytic cocktails) and "artificial hibernation" techniques, is reviewed (Laborit), and its further psychiatric clinical introduction in 1952, with initial discrepancies between the Parisian Val-de-Grâce (Laborit, Hamon, Paraire) and Sainte-Anne (Delay, Deniker) hospital groups. The first North-American publications on chlorpromazine took place in 1954 (Lehmann, Winkelman, Bower). The introduction of chlorpromazine in the USA (SKF) was more difficult due to their strong psychoanalytic tradition. The consolidation of the neuroleptic therapy took place in 1955, thanks to a series of scientific events, which confirmed the antipsychotic efficacy of the chlorpromazine.

Conclusions: The discovery of the antipsychotic properties of chlorpromazine in the 1950s was a fundamental event for the practice of psychiatry and for the genesis of the so-called "psychopharmacological revolution."

Similar articles

  • [The Praise of the Leak: A Tribute to Henri Laborit (1914-1995)]
    G Fond. Tunis Med 91 (8-9), 487-9. PMID 24227503.
    Henri Laborit (1914-1995) was a French military MD. He contributed to the discovery of an important molecule that has changed the face of psychiatry, namely chlorpromazin …
  • Neurosyphilis, Malaria, and the Discovery of Antipsychotic Agents
    FR Frankenburg et al. Harv Rev Psychiatry 16 (5), 299-307. PMID 18803105.
    Four of the most disabling human diseases are syphilis, malaria, schizophrenia, and manic-depressive illness. The history of the development of treatments for these seemi …
  • [Drug Treatments, From Chlorpromazine to New Molecules]
    A Gaillard et al. Soins Psychiatr (286), 25-9. PMID 23757890.
    The history of drug treatments, and particularly the discovery of certain molecules, led toan evolution in psychiatric practices. The discovery of the therapeutic propert …
  • A History of Antipsychotic Drug Development
    WW Shen. Compr Psychiatry 40 (6), 407-14. PMID 10579370. - Review
    The history of antipsychotic drug development has had a long and torturous course, often based on chance findings that bear little relationship to the intellectual backgr …
  • Monoaminergic Synapses and Schizophrenia: 45 Years of Neuroleptics
    MR Bennett. J Psychopharmacol 12 (3), 289-304. PMID 10958257. - Review
    In 1952 Delay and Deniker introduced the first antipsychotic, chlorpromazine, into the treatment of mental patients. They subsequently defined the word 'neuroleptic' to d …
See all similar articles

Cited by 47 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources